1.	A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer (CLEOPATRA) Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TOC4129g, WO20698, NCT00567190
2.	A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE) Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: BO22589, NCT01120184
3.	Pertuzumab and Cetuximab in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer That Did Not Respond to Previous Cetuximab Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: 07-070, U01CA062490, P30CA006516, CDR0000573125, DFCI-07070, 7881, NCT00551421
4.	Phase II Study of Pertuzumab in Patients With Hormone-Refractory Adenocarcinoma of the Prostate Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: MSKCC-03048, GENENTECH-TOC2682g, NCT00066755
5.	Phase II Study of Pertuzumab in Patients With Advanced Refractory or Recurrent Ovarian Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-0303080, GENENTECH-TOC2689g, NCT00070408
6.	Phase II Study of Pertuzumab in Patients With Refractory or Recurrent Non-Small Cell Lung Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-0405066-01, GENENTECH-TOC2572g, NCT00063154
7.	A Study to Evaluate Subjects Treated With rhuMab 2C4 (Pertuzumab) in a Previous Genentech Phase II Cancer Study Phase: Phase II Type: Treatment Status: Completed Age: Not specified Sponsor: Pharmaceutical / Industry Protocol IDs: TOC2664g, NCT00096941
8.	A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TOC3258g, NCT00096993
9.	A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer. Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: WO20697, NCT00545688
10.	A Study of the Combination of Erlotinib and Pertuzumab in Patients With Relapsed Non-Small Cell Lung Cancer (PENGUIN) Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TOC4603g, ML22485, GO01357, NCT00855894
11.	A Study of Trastuzumab-MCC-DM1 (T-DM1) in Combination With Pertuzumab Administered to Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TDM4373g, BO22495, NCT00875979
12.	A Study of Trastuzumab-MCC-DM1 (T-DM1) in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TDM4688g, NCT00943670
13.	A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Patients With HER2-Positive Breast Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: BO22280, 2009-012019-17, NCT00976989
14.	Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: SCRI GI 135, 108,079, NCT01121939
15.	Trastuzumab and Pertuzumab in Treating Patients With Unresectable Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Trastuzumab Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI, NIH WGMCC Protocol IDs: 060035, 06-C-0035, NCI-P6660, CDR0000462639, NCT00301899